Dotinurad is a selective uric acid reabsorption inhibitor used in the treatment of hyperuricemia and gout. It works by inhibiting the urate transporter 1 (URAT1) in the kidneys, which enhances uric acid excretion and lowers serum uric acid levels. This makes it effective in managing chronic gout, particularly in patients who do not respond adequately to other urate-lowering therapies. Due to its targeted mechanism, it offers a favorable safety profile with minimal impact on other renal transporters, reducing the risk of drug interactions and adverse effects. It is often considered for patients needing rapid and sustained reduction of uric acid to prevent gout flares and joint damage.